Chronic intestinal inflammation: Inflammatory bowel disease and colitis-associated colon cancer

Deborah C. Rubin  
*Washington University School of Medicine in St. Louis*

Anisa Shaker  
*Washington University School of Medicine in St. Louis*

Marc S. Levin  
*Washington University School of Medicine in St. Louis*

Follow this and additional works at: [http://digitalcommons.wustl.edu/open_access_pubs](http://digitalcommons.wustl.edu/open_access_pubs)

Recommended Citation
[http://digitalcommons.wustl.edu/open_access_pubs/2231](http://digitalcommons.wustl.edu/open_access_pubs/2231)

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Chronic intestinal inflammation: inflammatory bowel disease and colitis-associated colon cancer

Deborah C. Rubin1,2*, Anisa Shaker1 and Marc S. Levin1,3

1 Division of Gastroenterology, Department of Internal Medicine, Washington University School of Medicine, Saint Louis, MO, USA
2 Department of Developmental Biology, Washington University School of Medicine, Saint Louis, MO, USA
3 Saint Louis Veterans Administration Medical Center, Saint Louis, MO, USA

INTRODUCTION

The inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are chronic inflammatory disorders of the intestine. The prevalence in the United States is greater than 200 cases per 100,000, with the total number of IBD patients between 1 and 1.5 million. CD may affect all parts of the gastrointestinal tract, from mouth to anus, but most commonly involves the distal part of the small intestine or ileum, and colon. UC results in colonic inflammation that can affect the rectum only, or can progress proximally to involve part of or the entire colon. Clinical symptoms include diarrhea, abdominal pain, gastrointestinal bleeding, and weight loss. A serious long-term complication of chronic inflammation is the development of colorectal cancer. A genetic basis for IBD had long been recognized based on the increased familial risk. However, significant discordance for CD in twins, and a much less robust phenotypic concordance for UC, suggested additional factors play a role in disease pathogenesis, including environmental factors. In the past several years, progress in understanding the molecular basis of IBD has accelerated, beginning with the generation of animal models of colitis and progressing to the identification of specific genetic markers from candidate gene, gene linkage, and genome-wide association analyses. Genetic studies have also resulted in the recognition of the importance of environmental factors, particularly the crucial role of the gut microbiota in CD and UC. Altered immune responses to the normal intestinal flora are key factors in IBD pathogenesis. In this research topic, the genetic basis of IBD, the genetic and cellular alterations associated with colitis-associated colon cancer, and the emerging role of the intestinal microbiota and other environmental factors will be reviewed.

Keywords: inflammatory bowel disease, chronic intestinal inflammation, colitis-associated colon cancer, Crohn’s disease, ulcerative colitis

*Correspondence: Deborah C. Rubin, Division of Gastroenterology, Department of Internal Medicine, Washington University School of Medicine, 660 South Euclid Avenue, Box #134, Saint Louis, MO 63110, USA. e-mail: drubin@dom.wustl.edu

Published: 08 May 2012
doi: 10.3389/fimmu.2012.00107
Chronic inflammation is also associated with malignancy and has been proposed to be a major contributor to a multitude of cancers (Coussens and Werb, 2002; Kandala and Suri, 2006; Mantovani et al., 2008; Danese and Mantovani, 2010; Solinas et al., 2010). Chronic colonic inflammation from UC or CD results in a well-recognized increased risk of colon carcinogenesis (Bernstein et al., 2001). Eaden et al., 2001; Itzkowitz and Yeo, 2004; Ullman and Itzkowitz, 2011). CD is also associated with an increased risk of small bowel adenocarcinoma, due to chronic inflammation of the small intestine. The cumulative probability of CRC in UC patients has been shown in meta-analysis to range from 2% after 10 years of disease, up to 18% after 30 years of disease (Eaden et al., 2001; Feagins et al., 2009; Westbrook et al., 2010). Patients with Crohn’s colitis also had an increased cumulative risk for CRC, from 2.9% at 10 years to 8.3% after 30 years of disease (Canavan et al., 2006). The risk of carcinogenesis is related to severity, extent, and duration of disease (Rutter et al., 2004). Patients are advised to undergo colonoscopy with a specific biopsy protocol, performed every 1–2 years after 8–10 years of disease to detect dysplasia and rule out carcinogenesis. Unlike in sporadic colorectal carcinoma, in which the dysplastic lesion is an adenomatous polyp, dysplasia in IBD can be flat or polypoid. Flat lesions can be particularly difficult to detect endoscopically, and more sensitive markers of dysplasia are still lacking and represent a major focus of current research. Because of the frequency of CRC, the early onset of disease and the significantly increased risk for carcinogenesis, the health, emotional, and economic burden is quite high.

In this review, the genetic basis of IBD, the genetic and cellular alterations associated with chronic inflammation-induced colon cancer, and the emerging role of the intestinal microbiota and other environmental factors will be reviewed.

CLINICAL CHARACTERISTICS OF THE INFLAMMATORY BOWEL DISEASES
AND CROHN’S DISEASE

The peak age of incidence for IBD is between 16 and 30 years (Koster et al., 1999). Both UC and CD can affect the colon, and patients with either UC or CD have an increased risk of colitis-associated cancer (CAC) after 8–10 years from the time of diagnosis. Symptoms of active disease include diarrhea and abdominal pain. Although both CD and UC patients can experience gastrointestinal bleeding, in UC, hemorrhage or the presence of visible bleeding is more common than in CD, in which there is occult or microscopic blood loss. Extraintestinal manifestations of IBD include arthropathies and arthritis, skin diseases such as erythema nodosum and pyoderma gangrenosum, ocular disorders including uveitis and iritis, and sclerosing cholangitis, in which there is inflammation of the liver’s bile ducts. Urinary excretion of oxalate may be elevated in patients with CD, resulting in kidney stones, in patients who have not had a colectomy. Both UC and CD patients may develop strictures in the colon (UC or CD) or small bowel (CD only).

CLINICAL CHARACTERISTICS SPECIFIC TO CROHN’S DISEASE

Patients with CD suffer the consequences of a transmural inflammatory process and thus are at risk for fistulizing disease. Fistulas, which are communications between the gastrointestinal tract and other organs, may form between the bowel and bladder or the vagina, (e.g., enterovesicular or recto-vaginal fistulas), from the intestines to the skin (enterocutaneous fistulas), or from intestine to intestine (enteroenteric fistulas). Perianal disease is common and can be debilitating and refractory to treatment. Due to the transmural nature of the inflammatory process and involvement of the small intestine which is responsible for nutrient absorption, patients with CD are more prone to weight loss, nutrient deficiencies, and in children, growth retardation, especially after glucocorticoid therapy. Other serious complications include perforation or microperforation of the small or large bowel which may result in abscess formation. Surgical resection of the colon is not curative because CD can affect all parts of the gastrointestinal tract from mouth to anus. Pathological features specific to CD include the presence of granulomas on biopsy of the small bowel or colon.

CLINICAL CHARACTERISTICS SPECIFIC TO ULCERATIVE COLITIS

Colonic inflammation in UC is continuous, beginning in the rectum. Gross gastrointestinal bleeding is much more common in UC. The development of toxic megacolon is a dreaded complication of active inflammation, which may lead to emergent colectomy. Unlike in CD, colectomy is curative in UC.

MOUSE MODELS OF INFLAMMATORY BOWEL DISEASE

CHEMICAL MODELS

Mouse models of colitis and CAC have proven in selected circumstances to be relevant to the pathogenesis of these disorders in humans, have led to the identification of critical genetic factors and have provided a means for understanding the role of specific genes identified by linkage or genome-wide association studies. Two of the most widely used, non-genetic colitis models are the dextran sodium sulfate (DSS)-induced chemical injury model, and the trinitrobenzene sulfonic acid (TNBS) hapten-induced model (Strober et al., 2002). These have been particularly useful in identifying and studying the role of genetic factors that modify colitis, because both DSS and TNBS can be administered to genetically altered (knockout or transgenic) mice to rapidly induce colonic inflammation and ulceration resembling UC (Strober et al., 2002). DSS in drinking water induces an acute colitis within 5 days of exposure, and can also be utilized to mimic chronic colitis after repeated exposures. DSS in combination with azoxymethane (AOM) can be utilized to generate a mouse model of CAC (Greten et al., 2004; Neurath and Finazzo, 2009). TNBS is administered by enema and results in a hapten-induced, interleukin-12 (IL-12) driven colitis (Neurath and Finazzo, 2009).

GENETIC MODELS

The earliest murine genetic models of IBD were generated in mice in which the T-cell receptor was inactivated (Mombaerts et al., 1993), IL-10 (Kuhn et al., 1993) or IL-2 (Sadlack et al., 1993) was deleted, or tumor necrosis factor-alpha (TNFα−/− mice) was over-produced. These mice develop colitis after variable lengths of time, and a seminal discovery was the observation that in almost every genetic model, the microbiota are required for induction of disease.
of colitis (reviewed in Nell et al., 2010). Mice raised in either a germ-free environment (e.g., IL-10 mice; Sellon et al., 1998) or treated with antibiotics were protected from colitis. Subsequently, a plethora of mouse IBD models have been described, resulting from gene knockout or transgenic overexpression. As summarized in Rosenstiel et al. (2009), some mouse models correlate well with human disease risk loci or associated pathways, whereas others do not yet have clear relevance to human clinical syndromes.

GENETICS OF INFLAMMATORY BOWEL DISEASE

Exciting advances in the understanding of the complex genetics of IBD have resulted from comprehensive genetic studies including linkage and genome-wide association analyses. These have led to the identification of several predicted as well as novel pathways involved in CD and UC pathogenesis. For example, the critical roles of innate immunity and autophagy as well as epithelial barrier function have been supported by the identification of risk alleles in genes from these pathways, by genome-wide association studies (e.g., Duerr et al., 2006; Barrett et al. 2008; Silverberg et al., 2009). A complete list of genetic loci linked to IBD susceptibility (Kaser et al., 2010) shows that ancestry (Hugot et al., 2001; Ogura et al., 2001), and particularly associated with risk for CD in Caucasian populations of European ancestry (Lesage et al., 2002). Mutations in NOD2 are not sufficient for generating CD, as a significant proportion of the normal population has NOD2 mutations but are not affected by this disorder. However, individuals who are heterozygous for a NOD2 polymorphism have an increased risk of CD by a factor of 1.7–4, and homozygosity confers a risk factor of 11–27 (Economou et al., 2004). NOD2/CARD15 is a member of a family of cytosolic receptors containing a central nucleotide binding and oligomerization domain (NOD), an N-terminal effector binding domain, and leucine-rich repeats. These and other pattern recognition receptors, expressed in the epithelium and in a variety of immune cells, have important functions in innate immunity, particularly in regulating responses to intracellular pathogens and other exogenous injury-inducing stimuli. NOD2 recognizes components of the bacterial cell wall and elicits an NF-κB response, and also mediates the release of defensins, which are antimicrobial peptides. Mutations which impair NOD2 function result in defective downregulation of pro-inflammatory cytokines that normally occurs during chronic NOD2 stimulation (Hedl et al., 2007). In addition, in macrophages, others have shown that NOD2 is a negative regulator of Toll-like receptor 2 (TLR2)-mediated activation of NF-κB-c-Rel (Watanabe et al., 2004). However, the mechanisms by which loss of function mutations result in CD are still under investigation (Abraham and Cho, 2008). The discovery of NOD2 as an important regulator of T cell function and its importance in the pathogenesis of IBD has led to further research on the importance of the microbiome in CD pathogenesis.

Autophagy genes ATG16 autophagy related 16-like 1 (ATG16L1) and immunity related GTPase family M

Genome-wide association studies have shown that polymorphisms in the ATG16L1 gene (Hampe et al., 2007) and sequence variants in the IRGM gene (Parkes et al., 2007) are linked to CD. These genes encode proteins that are critical for autophagy, a process that mediates degradation of intracellular proteins and vesicle-mediated delivery to the lysosome (reviewed in Glick et al., 2010; Huett et al., 2010). Autophagy is particularly important for defense against intracellular pathogens. A mouse model of ATG16L1 deficiency showed Paneth cell dysfunction with aberrant exocytosis, as well as an altered transcriptional profile, characterized by increased expression of pro-inflammatory cytokines and lipid metabolism genes. Patients with CD have a similar Paneth cell phenotype (Cadwell et al., 2008). An important observation derived from the ATG16L1 mouse model was that viral infection with murine norovirus, as well as the presence of commensal bacteria, were required for generating these specific Paneth cell abnormalities (Miller et al., 2008). Germ-free mice have normal Paneth cells and viral infection in the presence of commensal bacteria induced the characteristic changes in Paneth cell function. IRGM functions to protect cells from mycobacteria (Singh et al., 2006). These data provide further support for the hypothesis that microbial/viral interactions with the intestinal mucosa are required for disease generation, and suggest that combinatorial models for IBD pathogenesis are most relevant for the study of human disease pathogenesis.

Innate immunity

NOD2/CARD15

A seminal discovery in unraveling the complex genetics underlying CD was that mutations in the NOD2/CARD15 gene locus are associated with risk for CD in Caucasian populations of European ancestry (Hugot et al., 2001; Ogura et al., 2001), and particularly associated with risk for CD in Caucasian populations of European ancestry (Lesage et al., 2002). Mutations in NOD2 are not sufficient for generating CD, as a significant proportion of the normal population has NOD2 mutations but are not affected by this disorder. However, individuals who are heterozygous for a NOD2 polymorphism have an increased risk of CD by a factor of 1.7–4, and homozygosity confers a risk factor of 11–27 (Economou et al., 2004). NOD2/CARD15 is a member of a family of cytosolic receptors containing a central nucleotide binding and oligomerization domain (NOD), an N-terminal effector binding domain, and leucine-rich repeats. These and other pattern recognition receptors, expressed in the epithelium and in a variety of immune cells, have important functions in innate immunity, particularly in regulating responses to intracellular pathogens and other exogenous injury-inducing stimuli. NOD2 recognizes components of the bacterial cell wall and elicits an NF-κB response, and also mediates the release of defensins, which are antimicrobial peptides. Mutations which impair NOD2 function result in defective downregulation of pro-inflammatory cytokines that normally occurs during chronic NOD2 stimulation (Hedl et al., 2007). In addition, in macrophages, others have shown that NOD2 is a negative regulator of Toll-like receptor 2 (TLR2)-mediated activation of NF-κB-c-Rel (Watanabe et al., 2004). However, the mechanisms by which loss of function mutations result in CD are still under investigation (Abraham and Cho, 2008). The discovery of NOD2 as an important regulator of T cell function and its importance in the pathogenesis of IBD has led to further research on the importance of the microbiome in CD pathogenesis.
implicated in CD, and is expressed by immature dendritic cells and memory T cells (Barrett et al., 2008).

**Interleukin-10**

Interleukin-10 is an anti-inflammatory cytokine that has long been postulated to play a key role in the development of the Th2 mouse models of IBD resulted from the generation of the IL-10 knockout mouse, which develops spontaneous inflammation (Kuhn et al., 1993), and which is dependent upon the presence of gut bacteria. Regulatory T cells (Tregs) express IL-10; selective deletion of IL-10 expression in Tregs results in spontaneous colitis and inflammation at other epithelial surfaces including skin and lungs (Robison et al., 2008). Genome-wide association studies for UC have shown SNPs flanking the IL-10 gene to be linked to UC (Frankie et al., 2008b). In addition, patients with early onset IBD (at less than 1 year of age) had mutations in the IL10RA and IL10RB genes, which resulted in abrogated STAT3 phosphorylation from deficient IL-10 signaling (Glocker et al., 2009). Interestingly, the phenotype of these patients is closest to CD, yet genome-wide association studies have not identified IL-10 as a susceptibility locus. However, these data all support a key role for IL-10 in IBD and suggest that future therapeutic trials with IL-10 may be warranted.

**NKX2.3**

Genome-wide association studies have shown that this homeodomain transcription factor is associated with CD and UC (Barrett et al., 2008; Frankie et al., 2008a). Mice that are null for Nkx2.3 have defective splenic and intestinal development. Homozygous null mice exhibit a marked delay in villus formation with crypt hypoproliferation. A subset of mice survive to adulthood and show massive hyperproliferation of the gut with decreased Bmp2 and Bmp4 expression (Pabst et al., 1999). Splenic development is markedly abnormal, in these mice, resulting in either small or completely absent spleens. Although the phenotype associated with Nkx2.3 mutations in humans has not been defined, mouse models suggest gut epithelial or splenic functional defects.

**T CELL-MEDIATED RESPONSES**

T helper cells differentiate into two distinct subtypes, Th1 and Th2 cells. These cells produce characteristic sets of cytokines. Many years of investigation has shown that Th1 cytokines are expressed in CD, whereas UC is a Th2 cytokine-mediated disease. A review of this vast body of research is beyond the scope of this manuscript, and is discussed in detail in other reviews (e.g., Strober and Fuss, 2011).

**ENVIRONMENTAL RISK FACTORS**

**SMOKING**

Smoking has emerged as one of the critically important risk factors for IBD, with an interesting paradoxical relationship for UC vs. CD disease activity. Smoking clearly increases the risk of CD activity (Calkins, 1989) and increases risk of recurrence after surgery (Unkert et al., 2008), yet appears to be protective for UC (Harries et al., 1982; Calkins, 1989). Nicotine has been studied as a primary treatment for UC (Pullan et al., 1994; Sandborn et al., 1997). Carbon monoxide, an important component of cigarette smoke, has been shown to suppress colonic pro-inflammatory cytokine production, and increase IL-10 secretion, through heme oxygenase-1 dependent pathways (Sheikh et al., 2011).

**THE MICROBIOME**

Bacterial, mycobacterial, or viral infections have long been postulated to be important in IBD pathogenesis (Lidar et al., 2009). A common feature of almost all rodent models of IBD is that treatment with antibiotics or rederivation of knockout or transgenic mice into germ-free conditions markedly mitigates disease activity (e.g., Taurog et al., 1994; Strober et al., 2002). Antibiotics can ameliorate disease activity in humans, and for certain complications of CD such as fistulizing disease, mesalazine is an important therapeutic agent. Viral infection is required to generate the Paneth cell defects found in ATG16L1 mice (Cadwell et al., 2010) suggesting that in addition to human bacterial microbiota, viral or fungal commensals may play a role in IBD pathogenesis.

**Associations with single microorganisms**

Microbial association studies in mouse models and analysis of intestinal mucosa or blood from patients with CD have implicated single pathogenic bacterial species in IBD pathogenesis, although none have yet been proven to be causative (reviewed in Lidar et al., 2009; Reiff and Kelly, 2010). The microorganisms most frequently implicated include *Mycobacterium avium* subspecies *paratuberculosis*, *Saccharomyces cerevisiae*, *Candida albicans*, adherent enteroinvasive *Escherichia coli*, and *Chlamydia pneumoniae*.

**The microbiome in normal intestine and in inflammatory bowel disease**

Recent discoveries implicating genes such as NOD2 in the pathogenesis of CD have led to the recognition that the pathogenesis of IBD involves loss of tolerance to commensal organisms and enhanced immune responses to bacterial antigens. The intestine is colonized by the largest bacterial burden in the body, containing approximately 100 trillion organisms (Gill et al., 2006). Bacteria belonging to the Firmicutes (Gram-positive bacteria) and Bacteroidetes (Gram-negative bacteria) phyla are the two major groups in mammalian intestine (Backhed et al., 2005; Turnbaugh et al., 2007). Proteobacteria (which include *Helicobacter* and *Escherichia*) and Actinobacteria are also significant contributors to the gut flora. Multiple studies have shown that the gut microbiota is altered in IBD patients. For example, biopsy samples from CD patients were used to prepare bacterial DNA which was amplified using universal bacterial 16S rRNA primers (Gophna et al., 2006). A significant increase in Proteobacteria and Bacteroidetes was found in CD patients compared to controls, with a decrease in Clostridia. Metagenomic approaches were used to analyze fecal samples from Crohn’s patients and healthy donors, and revealed reduced complexity of the Firmicutes in affected patients (Manichanh et al., 2008). Evaluation of the microbial populations in surgically resected tissue samples of small bowel and colon from Crohn’s, UC, and non-IBD controls, by rRNA sequence analysis, showed that specific flora were not enriched in small bowel or colon from IBD patients. However, a subset of IBD samples showed alterations...
in the representation of the Bacteroidetes and Firmicutes (Eckburg and Relman, 2007; Frank et al., 2007, 2011). Analysis of fecal samples from IBD patients compared to healthy subjects (Qin et al., 2010) showed reduced bacterial diversity and altered bacterial species abundance, using metagenomic sequencing methods.

**Role of Toll-like receptors and nucleotide-binding oligomerization domain protein-like receptors**

Toll-like receptors and NLRs are innate receptors that play an important role in recognizing commensal bacteria. Recognition of commensals by TLRs and NLRs has been shown to be critical for maintaining intestinal epithelial integrity and homeostasis. For example, mice deficient in the adaptor protein, MyD88, develop severe colitis following DSS administration (Rakoff-Nahoum et al., 2004). Inflammasomes composed of NLR proteins sense damage-associated molecular patterns. NLRPs inflammasome-deficient mice had more severe colitis, reduced IL-1β levels, and altered gut microbiota (Elmav et al., 2011).

**COLITIS/INFLAMMATION-ASSOCIATED DYSPLASIA AND CANCER**

**RELATIONSHIP TO COLORECTAL CANCER**

The pathogenetic mechanisms underlying CAC compared to familial or sporadic CRC have significant similarities, but major differences have also been recognized (Feagins et al., 2009; Terzic et al., 2010; Ullman and Itzkowitz, 2011). Whereas dysplasia in CRC is focal, multiple areas of the colon are often involved in CAC, indicating a broader “field effect.” Linkage analyses of families with rare, inherited early-onset CRC led to the identification of gene mutations which are highly relevant to the much more common sporadic CRC. In many circumstances, mutations in these genes also occur in CAC, but at a different stage of the disease, and other gene mutations are specific to CRC only. A seminal discovery in CRC pathogenesis was that inherited mutations in the adenomatous polyposis coli (APC) gene result in familial adenomatous polyposis or FAP, in which affected patients develop hundreds of adenomatous polyps and are at high risk for early death from CRC (Groden et al., 1991). APC mutations occur sporadically or as one of the earliest events in CRC pathogenesis. APC mutations are also found in CRC, but generally occur much later in the disease course (Redston et al., 1995; Tammin et al., 1995; Aust et al., 2002). On the other hand, KRAS and DCC/DPC4 mutations occur in both CAC and CRC (Ullman and Itzkowitz, 2011). P53 mutations are commonly found in CACs. P53 mutation is an early event that precedes loss of heterozygosity and is highly associated with aneuploidy (Brentnell et al., 1994). Chronic inflammation associated with increased pro-inflammatory cytokine release and signaling plays a critical role in the initiation of CAC, but sporadic CRC tumors also exhibit inflammatory infiltrates and activated immune response pathways (Terzic et al., 2010). These observations have led to the postulation that inflammation promotes tumorigenesis both extrinsically (driven by chronic inflammatory conditions such as IBD) and intrinsically (driven by inflammation and inflammatory cells recruited to and contained within tumors; Mantovani et al., 2008; Danes and Mantovani, 2010).

**MOUSE MODELS OF COLITIS-ASSOCIATED CANCER**

One of the most widely utilized mouse models of CAC is the AOM/DSS model (Becker et al., 2004; Greten et al., 2004; Suzuki et al., 2006; Neufert et al., 2007; Tanaka et al., 2008). AOM is a chemical carcinogen that acts by alkylation of DNA. It is further metabolized by the liver after intraperitoneal injection and is excreted in the bile. Additional metabolism by the bacterial flora further activates its carcinogenicity (Neufert et al., 2007). Multiple injections of AOM result in distal colonic tumorigenesis with histologic characteristics similar to human CRC. To mimic CAC, mouse models were developed that use AOM in combination with DSS, which when included in the drinking water, induces colitis, as above. The first models used AOM injection followed by one cycle of DSS. However, to further mimic states of chronic inflammation, AOM injection was combined with three cycles of DSS, which induces a chronic colitis. This model accelerates tumor formation and results in larger tumor size. Of interest, there are differences in susceptibility among mouse strains (Suzuki et al., 2006) and the formation of tumors in the same strain may vary among mouse facilities, suggesting that tumorigenesis is affected by microbiota.

**PATHOGENESIS AND MOLECULAR BIOLOGY OF COLITIS-ASSOCIATED CANCER**

Cancer associated with chronic inflammation, similar to other cancers, is characterized by a loss of normal growth regulation, resulting from a series of genetic mutations and epigenetic alterations in important cancer-related regulatory genes. The cancer stem cell model postulates that expansion of stem cells occurs in response to these mutations, resulting in tumor formation. The mechanisms by which inflammation results in carcinogenesis are presently the focus of intense research. Multiple pathways are likely to play a role, including production of reactive oxygen species and cytokine and chemokine expression by immune cells, which increase the risk of mutagenesis, and interactions between cancer stem cells and the local tumor microenvironment, including immune cells and myofibroblasts (Shaker et al., 2010; Vermeulen et al., 2010; Worthley et al., 2010; Quante et al., 2011; Shaker and Rubin, 2011). Inflammation also affects DNA methylation patterns and histone modification. Cyclo-oxygenase 2, which metabolizes arachidonic acid to prostaglandins, exhibits increased expression in inflamed tissues and affects cell proliferation, apoptosis, and angiogenesis. Genetic factors also play a role as IBD patients with a family history of CRC have an additional increase in risk for CRC, suggesting overlapping mechanisms.

**ROLE OF THE MICROBIOME, TLRs, AND NLRs**

In addition to playing an important role in IBD, TLRs and NLRs also contribute to the pathogenesis of CAC. For example, MyD88 signaling appears to be protective in the AOM/DSS model of CRC. MyD88–/– mice had increased polyp numbers compared to controls, and developed infiltrating carcinomas (Salcedo et al., 2010). In addition, derepression of the inflammasome in Casp12–/– mice, resulted in enhanced epithelial repair processes with increased proliferation, increased inflammation and increased susceptibility to AOM/DSS CAC (Dupaul-Chicoine et al., 2010).
An important mechanism of tumorigenesis is epigenetic silencing. Anderson, C. A., Massey, D. C., compared to adenocarcinoma with aging, had higher numbers of polyps (Greten et al., 2004; Grivennikov et al., 2009; Shaker et al., 2010). UC patients, associated with increased iNOS expression (Hussain et al., 2004). Mutations in codons 247 and 248 were found in inflamed colons of UC patients, associated with increased iNOS expression (Hussain et al., 2000). The major cytokines that play the best-described role in promoting inflammation in CAC include TNF-α, IL-1, and IL-6 (Ghezzi et al., 2004; Grivennikov et al., 2009; Shaker et al., 2010). TNF signaling via NF-kB pathways mediated downstream by IL-6 and STAT3 appear to play an important role in this disorder (Ullman and Itzkowitz, 2011).

**GENE SILENCING BY METHYLATION OR BY miRNA**

An important mechanism of tumorigenesis is epigenetic silencing of selected genes such as tumor suppressor genes, by promoter methylation or by microRNAs (miRNA). These include DNA mismatch repair (MMR) genes; hypermethylation is thought to be the mechanism responsible for loss of MMR activity. Loss of MMR activity results in microsatellite instability, which is characterized by increased frameshift mutation rates. MMR-deficient tumors account for approximately 15% of all CRCs and is characterized by increased frameshift mutation rates. MMR-deficient tumors account for approximately 15% of all CRCs and are characterized by a right sided location, have a lymphoctic infiltrate and have a poorly differentiated, mucinous, or signet cell histologic appearance.

**REFERENCES**


The methylation status of normal, inflamed, and dysplastic colonic tissue has been studied intensively. It has been proposed that gene methylation may be an early event in inflammation-associated tumorigenesis, and thus can potentially be a sensitive marker for predicting dysplasia. The methylation status of multiple genes has been examined, and generally, DNA methylation appears to be more frequent and is seen more commonly in non-neoplastic mucosa from UC patients with CAC, compared to non-neoplastic mucosa from UC patients without cancer. For example, the methylation status of RUNX2 and MINT1 was higher in non-neoplastic tissue of UC patients with CAC compared to non-neoplastic tissue of UC patients without cancer. In contrast, COX-2 was more frequently methylated in colons from UC patients without cancer compared to UC patients with cancer (Garrity-Park et al., 2010). Aging is associated with methylation and silencing of a panel of genes (including the estrogen receptor, MspII:p16-exon1, and CEP22). In non-dysplastic tissues from UC patients with high grade dysplasia, these genes also showed significantly higher degrees of methylation, compared to UC patients without dysplasia (Boa et al., 2001). Methylation of the estrogen receptor in non-neoplastic epithelium of UC patients with CAC occurred in a higher percentage compared to UC patients without cancer (Fujii et al., 2005). These data suggest that methylation status can be used as a biomarker for early detection of dysplasia, and also may help identify patients who are at increased risk for neoplasia.

**CONCLUSION**

Great progress has been made towards identifying the genetic basis for the IBD, and for understanding the interactions between the gut luminal/microbial environment and its epithelium. Future research will focus on understanding the function of identified disease risk genes and developing new targeted therapies. The burden of CAC continues to be high, and current research is focused on developing more sensitive markers of dysplasia. Intensive efforts will be focused on further delving into the mechanisms underlying the initiation of chronic inflammation-associated cancer, including the role of stromal–epithelial interactions within the unique environment of the gastrointestinal tract. As our understanding of gastrointestinal cancer stem cells progresses, so will our ability to optimally target the interactions between tumor epithelium and its microenvironment in CAC.

**ACKNOWLEDGMENTS**

The authors are supported by NIH NIDDK R01 DK 61216, 46122, 50466, and P30 DK 52574.
Rubin et al. Chronic intestinal inflammation and cancer


Rubin et al. Chronic intestinal inflammation and cancer

Penn et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer


Fujji et al. Chronic intestinal inflammation and cancer


Fugui et al. Chronic intestinal inflammation and cancer


Funk et al. Chronic intestinal inflammation and cancer

Fudenberg et al. Chronic intestinal inflammation and cancer


Fujii et al. Chronic intestinal inflammation and cancer


Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer

Caino et al. Chronic intestinal inflammation and cancer
Rubin et al. Chronic intestinal inflammation and cancer

Frontiers in Immunology | Inflammation May 2012 | Volume 3 | Article 10 | 8


"fimmu-03-00107" — 2012/5/7 — 16:51 — page 8 — #8


Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 18 January 2012; paper pending published: 31 January 2012; accepted: 17 April 2012, published online: 08 May 2012.


This article was submitted to Frontiers in Inflammation, a specialty of Frontiers in Immunology.

Copyright © 2012 Rubin, Shaker and Levin. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited.